A study of KJ-C2219 for the treatment of systemic sclerosis.
Latest Information Update: 05 Mar 2025
Price :
$35 *
At a glance
- Drugs KJ C2219 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- 05 Mar 2025 New trial record
Latest Information Update: 05 Mar 2025